Benitec Biopharma
BNTC
16 hedge funds and large institutions have $6.46M invested in Benitec Biopharma in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
251% more capital invested
Capital invested by funds: $1.84M → $6.46M (+$4.62M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
14% more funds holding
Funds holding: 14 → 16 (+2)
0.67% more ownership
Funds ownership: 0.47% → 1.14% (+0.67%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$3.54M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.15M |
| 3 |
Renaissance Technologies
New York
|
+$197K |
| 4 |
BlackRock
New York
|
+$110K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
-$462K |
| 2 |
Morgan Stanley
New York
|
-$438K |
| 3 |
VF
Virtu Financial
New York
|
-$116K |
| 4 |
Two Sigma Advisers
New York
|
-$61K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.1K |
BNTC Hedge Fund Activity: Q2 2021 in Review
16 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2021, worth a combined $6.46M — up 251% from $1.84M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BNTC positions and 5 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $3.54M. The largest seller was HighPoint Advisor Group, exiting entirely with an estimated $462K sold.
- 16 institutional investors held Benitec Biopharma (BNTC) as of Q2 2021, up from 14 in Q1 2021.
- Funds reported $6.46M of Benitec Biopharma stock for Q2 2021, up 251% quarter-over-quarter.
- 7 funds opened new Benitec Biopharma positions in Q2 2021 and 5 closed out, a net change of +2 holders.
- The largest Benitec Biopharma buyer in Q2 2021 was Suvretta Capital Management, an estimated $3.54M added.
- The largest Benitec Biopharma seller in Q2 2021 was HighPoint Advisor Group, an estimated $462K sold.
Based on aggregated 13F filings for Q2 2021.